Drugs / Lu-177-DOTA-girentuximab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02002312 | Aug 2011 → Jun 2015 | clear cell renal carcinoma | Radboud University Medical Center | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lu-177-DOTA-girentuximab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02002312 ↗ |
| Modality | Monoclonal antibody | “Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab” PMID 26706103 ↗ Dec 2015 |
| Route | Intravenous | “received 2405 MBq/m(2) of (177)Lu-girentuximab intravenously” PMID 26706103 ↗ Dec 2015 |
| Target | CA9 | “Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab” PMID 26706103 ↗ Dec 2015 |